Two items caught our eye this morning one which is big news the other not so big. Let’s cover the minor news first as the FDA officially approved semaglutide which will now be called Ozempic. While this is good news for Novo Nordisk (NYSE: NVO) frankly it is a minor event in the diabetes drug world. Ozempic now joins Trulicity from Lilly (NYSE: LLY) and Bydureon from AstraZeneca (NYSE: AZN) in the once-weekly GLP-1 category. Or put simply it’s a commodity.
We don’t to spend too much time on this, but Novo is truly in . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.